Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4395089 plus mirikizumab versus mirikizumab alone in adults with moderately to severely active Crohn's disease
2025-524112-11-00Phase 2Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial in Crohn's disease comparing LY4395089 + mirikizumab with mirikizumab (2 arms). Primary endpoints: Percentage of participants with Crohn's disease who achieve endoscopic response and Proportion of participants achieving endoscopic response at Week 12 of Study Period 1. Planned start Aug 2026; status: authorised.
02
Drugs
LY4395089mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2025-524112-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524112-11-00.